Life Science & Technology Park
1951 NW 7th Avenue, Suite 300
About LongeveronLongeveron is a regenerative medicine therapy company founded in 2014. Longeveron's goal is to provide the first of its kind biological solution for aging-related diseases, and is dedicated to developing safe cell-based therapeutics to revolutionize the aging process and improve quality of life. The company's research focus areas include Alzheimer's disease, Aging Frailty and the Metabolic Syndrome. Longeveron produces LMSCs in its own state-of-the-art cGMP cell processing facility.
Co-Founder and CSO: Joshua M. Hare, M.D.
20 articles with Longeveron
Longeveron LLC Announces Completion of Enrollment in Phase 2b Clinical Trial of Longeveron Allogeneic Mesenchymal Stem Cells (LMSCs) in Aging Frailty.
MIAMI , Feb. 12, 2020 /PRNewswire/ -- Longeveron LLC, a leading developer of adult stem cell technologies for aging-related and life-threatening conditions, announced today that it has completed enrollment in its Phase 2b Aging Frailty trial. This double-blinded, randomized, placebo-controlled study is designed to evaluate the safety and efficacy of LMSCs in patients with m
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
Longeveron Discusses Latest Stem Cell Findings for Aging Frailty at the International Conference on Frailty & Sarcopenia Research
Longeveron's session, "Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells as a Treatment for Aging-Related Indications," is scheduled for Thursday, February 21 at 11:40 am.
Longeveron will be a speaker at the 2018 Maryland Technology Development Corporation (TEDCO) Entrepreneur Expo & Stem Cell Symposium, to be held October 30 at the Hotel at the University of Maryland.
Grant will be applied to Longeveron's Aging Frailty stem cell research
Longeveron Chief Science Officer Dr. Joshua Hare To Keynote 2018 HEALinc Future Health Innovation Summit
Longeveron, a biopharmaceutical company that develops stem cell therapies, announced that Co-Founder and Chief Science Officer Joshua Hare, M.D. will be a keynote speaker at the 2018 HEALinc Future Health Innovation Summit, to be held Oct. 7-9 at the Melia Nassau Beach Hotel, Nassau, Bahamas.
9/4/2018Biopharm companies closed out August with a plethora of changes to executive and senior leadership positions. Let's take a look.
Longeveron, a biopharmaceutical company that develops stem cell therapies for aging-related diseases, announced that the company has appointed Arin Maercks as chief commercial officer.
Dr. Joshua Hare To Present Longeveron Regenerative Stem Cell Research At The Sixth Annual Aspen BrainLab
Longeveron LLC announced that Dr. Joshua Hare, Chief Science Officer, will present at the sixth annual Aspen BrainLab on July 14.
Concerns Rise Over Negative Impact of HEV Light on Skin as Companies Delve Into Anti-Aging Therap...
6/22/2018Something that most everyone does multiple times a day may not be as care-free as initially thought. Taking a selfie with a smart phone can actually be harmful to your skin.
Longeveron LLC announced that it is currently recruiting for a Phase 1 clinical trial to evaluate the safety and efficacy of its allogeneic Mesenchymal Stem Cells (MSCs) in patients with Alzheimer's disease.
Longeveron Shares Promising State of Regenerative Medicine Research With Experts at the FDA, NIH and Other Leading Organizations at National Conference
A single injection of the allogeneic mesenchymal stem cells, in fact, was associated with significant gains in functional capacity in both Phase I and Phase II studies Longeveron published in The Journals of Gerontology in 2017.
NIH Awards Longeveron Cutting-Edge Research Grant to Fight 'Metabolic Syndrome' of Obesity, High Blood Pressure, Unhealthy Cholesterol and More through Regenerative Medicine
The NIA recognized this, and recently awarded a prestigious research grant to Longeveron, a regenerative medicine therapy company based in Miami, Florida.
The company is building on Phase 1 safety and Phase 2 safety, tolerability and efficacy studies conducted by the University of Miami Miller School of Medicine of Allogeneic MSCs in patients with aging frailty.
Longeveron announced that the company is progressing with the development of its stem cell treatment to ameliorate aging frailty.
Longeveron Announces Publication Of Phase l Safety And Efficacy Trial Results For Allogeneic Stem Cell Treatment In Frailty Patients
Longeveron Begins Enrollment Of Second Cohort Of Phase I Trial Of Allogeneic Mesenchymal Stem Cells To Treat Alzheimer's Disease Patients